Showing results (1-10 of 237) with videos related to
Sort By:
Pageof 24
Pharmacogenomics|January 23, 2020
Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intakeHai le Ba, Litaty Mbatchi, Florence Gattacceca, et al.Current Medicinal Chemistry. Anti-Cancer Agents|March 23, 2004
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde storyJoseph Ciccolini, Alexandre Evrard, Pierre CuqPharmacogenomics|March 3, 2012
CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigationsJoseph Ciccolini, Alexandre Evrard, Lithaty M'Batchi, et al.Expert Review of Clinical Pharmacology|May 17, 2018
Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticlesAnne Rodallec, Raphaelle Fanciullino, Bruno Lacarelle, et al.Annales De Biologie Clinique|October 23, 2014
[Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs]Anne-Sophie Chantry, Sylvie Quaranta, Joseph Ciccolini, et al.Critical Reviews in Oncology/Hematology|August 12, 2018
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncologyAnne Rodallec, Sebastien Benzekry, Bruno Lacarelle, et al.Clinical Colorectal Cancer|October 6, 2010
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?Joseph Ciccolini, Eva Gross, Laetitia Dahan, et al.Nature Reviews. Clinical Oncology|November 25, 2015
Computational oncology--mathematical modelling of drug regimens for precision medicineDominique Barbolosi, Joseph Ciccolini, Bruno Lacarelle, et al.Cancer Chemotherapy and Pharmacology|November 18, 2005
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiencyJoseph Ciccolini, Cedric Mercier, Laetitia Dahan, et al.Current Topics in Medicinal Chemistry|September 18, 2012
100% human monoclonal antibodies in oncology: hype or breakthrough?Stephan Benay, Raphaelle Fanciullino, Cedric Mercier, et al.Pageof 24